Fig. 8

BREGRS is a promising tool to evaluate the immunotherapeutic response. (A) The association of BREGRS with the response levels of immune-related pathways. (B, D) The expression level of the HLA family and immune checkpoint genes in the TCGA-BLCA (B), IMvigor210 (C), and Riaz (D) cohorts. (E) The expression difference of the HLA family and immune checkpoint genes between the low- and high-BREGRS subjects. (F) The association between the BREGRS stratification and immunotherapeutic response. (G) ROC analyses indicating the predictive ability of BREGRS for the response to immunotherapy. (H, I) Cases with high BREGRS suffering unfavorable OS both in the IMvigor210 (H) and Riaz (I) cohorts. (J) Subgroup analyses of BREGRS in the IMvigor210 cohort. HLA, human leukocyte antigen; *P < 0.05; **P < 0.01; ***P < 0.001